Cronos Group (CRON) AI Stock Analysis

• Market Cap: $1.37B
• Dividend Yield: N/A
• Average Volume (3M): 179.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.49
• Revenue Growth: 22.20%
• EPS Growth: N/A
• Country: CA
• Employees: 459
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 379,051,120
• 10 Day Avg. Volume: 168,591
• 30 Day Avg. Volume: 179,686
• PEG Ratio: 0.84
• Price to Book (P/B): 0.92
• Price to Sales (P/S): 6.74
• P/FCF Ratio: 6.63K
• Enterprise Value/Market Cap: 0.16
• Enterprise Value/Revenue: 1.45
• Enterprise Value/Gross Profit: 3.41
• Enterprise Value/Ebitda: 6.60
• 1Y Price Target: $3.96
• Price Target Upside: 9.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): 0.09
• Revenue Forecast (FY): $188.00M

• Rating: 60 Neutral
• Price Target: C$4.00 ▲(10.80% Upside)
• Action: Reiterated Date: 03/01/26
• Date: Action: Reiterated 03/01/26

The score is supported primarily by a very strong balance sheet and improving operational trends (revenue growth and margin recovery), reinforced by a constructive earnings-call outlook and market-share gains. This is tempered by ongoing and volatile profitability, uneven free-cash-flow conversion in 2025, and weak valuation signals due to a negative P/E.

Positive Factors

Very low leverage / strong capital structure

Extremely low debt-to-equity provides durable financial flexibility, lowering refinancing and interest risks while enabling funding for expansion or R&D without pressuring cash flows. This underpins long-term stability and resilience across regulatory or market cycles.

Large cash reserves and no debt

Very high cash balances and absence of debt support multi-quarter investment in capacity, product development, and international market entry without needing dilutive financing. It also provides a buffer to weather regulatory or demand volatility over months.

Market leadership and international growth

Clear brand leadership in key categories and rising international revenue (Israel growth) reflect durable competitive positioning, distribution strength, and portfolio diversification. Leading market shares support pricing power and longer-term revenue resilience.

Negative Factors

Weak operating cash generation

Persistently negative free cash flow growth and operating cash coverage well below net income indicate cash generation shortfalls. Over months this can constrain capex, delay strategic investments, or force financing even with high cash balances, reducing optionality.

Negative operational profitability

A deeply negative EBIT margin signals ongoing core business losses despite revenue growth, limiting sustainable earnings conversion. Low ROE shows capital is not generating attractive returns, challenging long-term shareholder value creation absent margin recovery.

Production and logistics constraints

Ongoing supply and shipment timing problems create structural execution risk: they can impair category sales mix, cede shelf space to competitors, and hamper consistent revenue recognition across quarters, reducing reliability of growth plans until capacity issues are resolved.

Cronos Group Business Overview & Revenue Model

Company Description

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

How the Company Makes Money

Cronos Group generates revenue primarily through the sale of cannabis products in both domestic and international markets. The company's revenue streams include wholesale sales to licensed distributors and retailers, direct-to-consumer sales through its own online platforms, and partnerships with other companies to co-develop and market cannabis products. Significant partnerships, such as those with major players in the pharmaceutical and consumer goods sectors, allow Cronos to expand its reach and diversify its product offerings. Additionally, the company benefits from the growing legalization of cannabis in various regions, enabling it to tap into new markets and increase its customer base.

Cronos Group Financial Statement Overview

Summary

Balance sheet strength is a major positive (very low leverage and large equity cushion), and operations show improvement with accelerating revenue growth and materially better gross margins. Offsetting this, profitability remains weak and inconsistent (operating losses persist and net income swung from 2024 profit back to a 2025 loss), and free cash flow fell to near breakeven in 2025 despite positive operating cash flow.

Income Statement

Revenue growth is improving, with 2025 up 12.4% after a sharp slowdown in 2024 (+0.35%) and essentially flat 2023 (-0.6%). Profitability has also improved materially versus prior years (gross margin rose to ~41% in 2025 from ~26% in 2024 and ~14% in 2023). However, the company remains structurally unprofitable on an operating basis (2025 operating margin ~-12% and EBITDA margin ~-2%), and net income swung from a large positive in 2024 (~35% net margin) back to a loss in 2025 (~-6% net margin), indicating earnings volatility and limited consistency in bottom-line results.

Balance Sheet

The balance sheet is a clear strength: leverage is extremely low (debt-to-equity roughly ~0.2%–0.7% across 2020–2025), with over $1.0B of equity supporting ~$1.19B of assets in 2025. This provides meaningful financial flexibility and reduces solvency risk. The main weakness is that returns on equity have been inconsistent and often negative (loss years in 2021–2023 and 2025), which suggests the capital base is not yet being translated into durable profitability.

Cash Flow

Cash generation has improved versus 2020–2023, with operating cash flow turning positive in 2024 ($18.8M) and rising further in 2025 ($26.3M). That said, free cash flow deteriorated sharply in 2025 to near breakeven (~$0.15M) from $5.7M in 2024, implying higher cash outflows (e.g., reinvestment or working-capital pressure). Cash flow quality versus reported earnings is mixed: 2025 produced positive operating cash flow despite a net loss, while 2024’s cash flow covered only a modest portion of net income (suggesting earnings may have included non-cash or one-time benefits).

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	149.15M	117.50M	87.03M	87.54M	64.02M
Gross Profit	61.70M	30.45M	11.88M	15.58M	-17.45M
EBITDA	-3.36M	-45.37M	-72.28M	-93.81M	-150.79M
Net Income	-9.61M	41.04M	-73.79M	-170.26M	-392.81M
Balance Sheet
Total Assets	1.19B	1.17B	1.14B	1.21B	1.40B
Cash, Cash Equivalents and Short-Term Investments	830.28M	858.80M	861.53M	877.72M	1.00B
Total Debt	2.68M	2.02M	2.55M	3.88M	9.81M
Total Liabilities	54.08M	55.33M	43.96M	72.05M	63.46M
Stockholders Equity	1.09B	1.06B	1.10B	1.14B	1.34B
Cash Flow
Free Cash Flow	151.61K	5.69M	-46.26M	-93.98M	-165.88M
Operating Cash Flow	26.32M	18.84M	-42.84M	-88.95M	-153.62M
Investing Cash Flow	-77.90M	175.15M	-59.50M	-1.84M	-28.90M
Financing Cash Flow	-20.25M	-1.23M	-1.03M	-2.90M	-13.44M

Cronos Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.61
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CRON, the sentiment is Negative. The current price of 3.61 is below the 20-day moving average (MA) of 3.61, below the 50-day MA of 3.67, and above the 200-day MA of 3.35, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 48.21 is Neutral, neither overbought nor oversold. The STOCH value of 53.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CRON.

Cronos Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GTII	65 Neutral	C$2.02B	12.85	6.18%	―	6.18%	-28.69%
CRON	60 Neutral	$1.37B	-106.80	-0.88%	―	22.20%	―
TRUL	56 Neutral	C$1.57B	-9.64	-9.14%	―	4.27%	3.41%
CL	52 Neutral	C$556.15M	-6.05	-11.79%	―	-6.48%	22.63%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CURA	50 Neutral	C$2.34B	-6.83	-27.48%	―	-3.38%	-31.35%
WEED	46 Neutral	C$539.72M	-0.81	-47.80%	―	-0.67%	58.98%

Cronos Group Corporate Events

Cronos Group Posts Record 2025 Revenue and Eyes European Cannabis Expansion

Cronos Group reported record fourth-quarter and full-year 2025 net revenue, with Q4 sales rising 47% year over year to $44.5 million and full-year revenue up 25% to $146.6 million, driven by strong demand for its leading brands, expanded output from Cronos GrowCo and growing international contributions, particularly in Israel. The company significantly improved profitability metrics, turning Adjusted EBITDA positive for the year, while maintaining an industry-leading cash position of $832 million plus short-term investments, which, along with the pending acquisition of European operator CanAdelaar and its Netherlands adult-use strategy, is expected to strengthen its competitive footing and support sustained growth and long-term value creation.

The most recent analyst rating on (TSE:CRON) stock is a Buy with a C$4.50 price target. To see the full list of analyst forecasts on Cronos Group stock, see the TSE:CRON Stock Forecast page.